Anderson Raymond 的 Form 4/A 修正申報

修正

Monopar Therapeutics（MNPR），2026/8/28 申報

申報編號: 0001437749-26-029228
申報時間: 2026/8/28 19:41 ET
交易日: 2026/8/25
申報延遲: 3 天
10b5-1 計畫: 有勾選
原始申報日: 2026/8/27

SEC EDGAR 原文（在新分頁開啟）

這份申報列了 5 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $35.2 萬。交易後 3 天申報。

這份修正申報取代了 0001437749-26-029115（2026/8/27 申報）。

申報人

一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人	與公司的關係
Anderson RaymondCIK 0001362489	董事

非衍生性證券（表 I）

普通股等股票的取得與處分，每一列是申報上的一筆。

非衍生性證券的交易
交易日	證券	交易	股數	價格	金額	交易後持股	持有方式
2026/8/25	Common Stock	M行使選擇權取得	+1,402	$30.00	+$42,060	6,775	直接
2026/8/25	Common Stock	M行使選擇權取得	+1,740	$30.00	+$52,200	8,515	直接
2026/8/25	Common Stock	S賣出處分	−694	$110.04^F4	−$76,367.76	7,821	直接
2026/8/25	Common Stock	S賣出處分	−646	$111.07^F5	−$71,751.22	7,175	直接
2026/8/25	Common Stock	S賣出處分	−1,802	$113.05^F6	−$203,716.1	5,373	直接

衍生性證券（表 II）

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日	證券	交易	標的股數	單價	金額	交易後持有	持有方式	旗標
2026/8/25	Common Stock	M行使選擇權取得	+1,402	$0.00	$0	2,803	直接
2026/8/25	Common Stock	M行使選擇權取得	+1,740	$0.00	$0	3,480	直接

附註與備註

本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

表 I 有 1 筆交易的價格引用這則附註。

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

表 I 有 1 筆交易的價格引用這則附註。

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

表 I 有 1 筆交易的價格引用這則附註。

備註

On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan. The prior Form 4 also did not account for Monopar Therapeutics Inc.'s 5 to 1 reverse stock split of its common stock, which was effected August 12, 2024 (the "Reverse Stock Split"). The amount of securities reported on this amended Form 4 have been adjusted to reflect the Reverse Stock Split.

看 SEC EDGAR 上的完整原文（在新分頁開啟）